Motiani et al. explored the selective requirement of many breast cancer cell lines for the use of Orai3 as opposed to the canonical Orai1-mediated SOCE based on the presence or absence of plasma membrane estrogen receptors [155]. The gene discussed is ORAI3; the disease is breast carcinoma.